Veru Inc. (VERU) stock
VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
$2.14+0.06 (+2.88%)
Close on Nov 17, 2026Market cap $36.49MP/E –Yield –
Veru r&d expenses
Research and development expenses are spending on new products and technology.
Veru's R&D Expenses for the twelve months ending Jun 30, 2026 was $11.76M, down 26.3% year over year. For fiscal 2025 it was $15.59M, up 22.0% from the year before. Over ten years it grew 53.1% a year on average. The highest annual figure on record is $70.91M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.59M | +22.0% |
| FY2024 | Sep 30, 2024 | $12.78M | -75.0% |
| FY2023 | Sep 30, 2023 | $51.20M | -27.8% |
| FY2022 | Sep 30, 2022 | $70.91M | +116.9% |
| FY2021 | Sep 30, 2021 | $32.69M | +93.1% |
| FY2020 | Sep 30, 2020 | $16.94M | +23.2% |
| FY2019 | Sep 30, 2019 | $13.74M | +26.7% |
| FY2018 | Sep 30, 2018 | $10.85M | +252.7% |
| FY2017 | Sep 30, 2017 | $3.08M | +2995.2% |
| FY2016 | Sep 30, 2016 | $99.39K | -54.8% |
| FY2015 | Sep 30, 2015 | $219.82K | +3842.9% |
| FY2014 | Sep 30, 2014 | $5.58K | +17.5% |
| FY2013 | Sep 30, 2013 | $4.75K | -10.1% |
| FY2012 | Sep 30, 2012 | $5.28K | -51.7% |
| FY2011 | Sep 30, 2011 | $10.93K | +2768.5% |
| FY2010 | Sep 30, 2010 | $381 | -99.6% |
| FY2009 | Sep 30, 2009 | $105.92K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $4.35M | +44.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $3.15M | -20.0% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $1.34M | -76.5% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $2.92M | -11.3% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $3.02M | -37.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $3.93M | +31.7% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $5.72M | +244.7% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $3.29M | -16.5% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $4.85M | -44.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $2.99M | -83.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $1.66M | -92.0% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $3.94M | -85.5% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $8.79M | -51.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $17.86M | +14.9% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $20.61M | +104.5% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $27.16M | +228.9% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $18.13M | +62.1% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $15.54M | +105.2% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $10.08M | +77.6% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $8.26M | +152.6% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $11.19M | +152.2% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $7.57M | +92.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $5.68M | +7.1% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $3.27M | -9.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $4.44M | -8.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $3.93M | +35.0% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $5.30M | +124.4% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $3.61M | +19.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $4.87M | +28.5% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $2.91M | +40.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $2.36M | +20.6% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $3.03M | +116.4% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $3.79M | +1153.9% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $2.08M | +72.0% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $1.96M | +1044.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $1.40M | +42891.1% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $302.07K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $1.21M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $171.10K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $3.26K | – |
See a number that looks wrong?